ES2494840T3 - Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas - Google Patents

Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Download PDF

Info

Publication number
ES2494840T3
ES2494840T3 ES06723429.4T ES06723429T ES2494840T3 ES 2494840 T3 ES2494840 T3 ES 2494840T3 ES 06723429 T ES06723429 T ES 06723429T ES 2494840 T3 ES2494840 T3 ES 2494840T3
Authority
ES
Spain
Prior art keywords
seq
hbv
hepatitis
polynucleic acid
nucleoside analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06723429.4T
Other languages
English (en)
Inventor
Mithat Bozdayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Fujirebio Europe NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Europe NV SA filed Critical Fujirebio Europe NV SA
Application granted granted Critical
Publication of ES2494840T3 publication Critical patent/ES2494840T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un ácido polinucleico de VHB aislado que codifica una variante de VHB, dicho ácido polinucleico de VHB comprende una mutación nucleotídica que produce sustitución de aminoácidos rtA181S del gen de la ADN polimerasa en la variante de VHB, en donde dicha mutación nucleotídica produce una sensibilidad disminuida al análogo de nucleósido adefovir y lamivudina, dicho ácido polinucleico de VHB comprende un ácido polinucleico elegido del grupo que consiste en SEQ ID 2, SEQ ID 3, SEQ ID 5, SEQ ID 6 y SEQ ID 7.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23

Claims (1)

  1. imagen1
    imagen2
ES06723429.4T 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Active ES2494840T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66148405P 2005-03-15 2005-03-15
US661484P 2005-03-15
EP05101997 2005-03-15
EP05101997 2005-03-15
PCT/EP2006/002352 WO2006097285A1 (en) 2005-03-15 2006-03-14 Hepatitis-b viral variants with reduced susceptibility to nucleoside analogs and uses thereof

Publications (1)

Publication Number Publication Date
ES2494840T3 true ES2494840T3 (es) 2014-09-16

Family

ID=35355552

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06723429.4T Active ES2494840T3 (es) 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas

Country Status (10)

Country Link
US (1) US7422848B2 (es)
EP (1) EP1858916B1 (es)
JP (1) JP2008537483A (es)
CN (1) CN101203528A (es)
AU (1) AU2006224789B2 (es)
ES (1) ES2494840T3 (es)
NZ (1) NZ562467A (es)
PL (1) PL1858916T4 (es)
PT (1) PT1858916E (es)
WO (1) WO2006097285A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO351996A0 (en) * 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
USRE40233E1 (en) 1996-11-08 2008-04-08 Melbourne Health Viral variants and methods for detecting same
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
TR200402517T1 (tr) 2002-03-29 2007-12-24 Innogenetics N.V. HBV ilaç direnci tespit metotları
EP2455390A1 (en) * 2002-04-12 2012-05-23 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
PT1858915E (pt) * 2005-03-15 2014-06-11 Justus Liebig Universität Giessen Variantes do vírus de hepatite b resistentes contra alguns análogos de nucleósido, mas sensíveis a outros, e suas utilizações
AU2006230802A1 (en) * 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
JP2008534020A (ja) 2005-04-08 2008-08-28 メルボルン ヘルス 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
JP2009213465A (ja) * 2007-10-30 2009-09-24 Toshiba Corp Ｂ型肝炎ウイルス薬剤耐性株検出用核酸プライマーセット、アッセイキットおよびｂ型肝炎ウィルスの薬剤耐性株の検出方法
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576175A (en) 1989-09-20 1996-11-19 Immuno Aktiengesellschaft Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
US5849987A (en) 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5858328A (en) 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
EP0968648A1 (en) 1992-07-08 2000-01-05 N.V. Innogenetics S.A. Mammalian nonhuman transgenic animal having a constitutive or inducible expression of the human endonexin II gene or its muteins or its fragments
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US6100068A (en) 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5817457A (en) 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
ZA973367B (en) 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
DE69715621T2 (de) 1996-04-26 2003-05-22 Massachusetts Inst Technology Drei hybriden screening test
CA2262515A1 (en) 1996-08-16 1998-02-26 Dong Wha Pharm. Ind. Co., Ltd. Hbv polymerase, rnase h enzyme derived from hbv polymerase, processes for preparation and uses for screening antiviral agents thereof
AUPO351996A0 (en) 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US5939541A (en) 1997-03-28 1999-08-17 University Of South Carolina Method for enhancing expression of a foreign or endogenous gene product in plants
US6610471B1 (en) 1998-01-21 2003-08-26 The Penn State Research Foundation Methods and compositions to investigate infection by hepatitis B virus and agents to prevent and treat the infection
US6150105A (en) 1998-08-20 2000-11-21 Genetic Assays, Inc. Methods of screening nucleic acids for nucleotide variations
JP2000270876A (ja) 1999-03-26 2000-10-03 Genome Science Laboratories Co Ltd Ｂ型肝炎ウイルス遺伝子の変異検出方法および検出キット
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
AU779112B2 (en) 1999-04-30 2005-01-06 Sequenom, Inc. Diagnostic sequencing by a combination of specific cleavage and mass spectrometry
EP2319917A3 (en) * 2002-02-07 2012-02-08 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
TR200402517T1 (tr) 2002-03-29 2007-12-24 Innogenetics N.V. HBV ilaç direnci tespit metotları
EP2455390A1 (en) * 2002-04-12 2012-05-23 Melbourne Health Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
EP1546190A2 (en) 2002-10-01 2005-06-29 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
PT1858915E (pt) 2005-03-15 2014-06-11 Justus Liebig Universität Giessen Variantes do vírus de hepatite b resistentes contra alguns análogos de nucleósido, mas sensíveis a outros, e suas utilizações

Also Published As

Publication number Publication date
JP2008537483A (ja) 2008-09-18
AU2006224789B2 (en) 2012-09-06
WO2006097285A1 (en) 2006-09-21
EP1858916B1 (en) 2014-07-09
PL1858916T4 (pl) 2015-04-30
NZ562467A (en) 2011-07-29
CN101203528A (zh) 2008-06-18
AU2006224789A1 (en) 2006-09-21
PL1858916T3 (pl) 2015-01-30
US7422848B2 (en) 2008-09-09
PT1858916E (pt) 2014-10-06
EP1858916A1 (en) 2007-11-28
US20060234212A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ES2494840T3 (es) Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
US10981137B2 (en) Enrichment of DNA sequencing libraries from samples containing small amounts of target DNA
CY1120186T1 (el) Τροποποιημενα νουκλεοτιδια για αλληλουχιση πολυνουκλεοτιδιωn
ES2304739T3 (es) Metodos de genotipaje utilizando diferencias en la temperatura de fusion.
ATE557084T1 (de) Modifizierte dna-polymerasen zur verbesserten inkorporation von nukleotidanaloga
Kim et al. The complete mitochondrial genome of Anisakis simplex (Ascaridida: Nematoda) and phylogenetic implications
RU2011137526A (ru) Способ амплификации gс-богатых матриц днк
Jung et al. Development of RNA aptamer that inhibits methyltransferase activity of dengue virus
WO2007016668A3 (en) Methods and compositions for disease prognosis based on nucleic acid methylation
JP2022520574A (ja) テンプレートなしの酵素によるポリヌクレオチド合成における効率的生成物切断
MXPA02011896A (es) Produccion combinatoria de analogos de nucleotidos y nucleosidos (xitp).
WO2008082440A3 (en) Fluorescent nucleoside analogues
US20230130605A1 (en) Dna polymerase theta mutants, methods of producing these mutants, and their uses
EP1799814A4 (en) VARIANTS OF HEPATITIS B VIRUS HAVING RESISTANCE TO ANTIVIRAL NUCLEOSIDE AGENTS AND THEIR APPLICATIONS
Haasnoot et al. The Brome mosaic virus subgenomic promoter hairpin is structurally similar to the iron-responsive element and functionally equivalent to the minus-strand core promoter stem-loop C.
Mortazavi et al. Bioinformatic identification of rare codon clusters (RCCs) in HBV genome and evaluation of RCCs in proteins structure of Hepatitis B Virus
JP2008534020A5 (es)
WO2008136470A1 (ja) Ｈｃｖ遺伝子
Furano et al. Cryptic genetic variation enhances primate L1 retrotransposon survival by enlarging the functional coiled coil sequence space of ORF1p
ES2609586T3 (es) Secuencias de nucleótidos y aminoácidos que codifican una proteína exportada 1 derivada de Plasmodium vivax y usos de las mismas
Tarashima et al. Synthesis of DNA fragments containing 2′-deoxy-4′-selenonucleoside units using DNA polymerases: Comparison of dNTPs with O, S and Se at the 4′-position in replication
JP2019140953A5 (es)
WO2008091283A3 (en) Viral inhibitory nucleotide sequences and vaccines
WO2003093461A3 (fr) Banque genomique du cyanophage s-2l et analyse fonctionnelle
RU2009104533A (ru) Способы обнаружения болезни альцгеймера